Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125. https://doi.org/10.1056/NEJMoa1713137

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50. https://doi.org/10.1056/NEJMoa1913662

Article  CAS  PubMed  Google Scholar 

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640. https://doi.org/10.1056/NEJMoa1612674

Article  CAS  PubMed  Google Scholar 

van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, Steeghs N (2023) Therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacokinet 62:1333–1364. https://doi.org/10.1007/s40262-023-01293-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki M, Komizo N, Iihara H, Hirose C, Yanase K, Yamada Y, Endo J, Yamashita S, Ohno Y, Todoroki K, Suzuki A, Hayashi H (2023) Relationship between osimertinib concentration and clinical response in Japanese patients with non-small cell lung cancer. Anticancer Res 43:725–732. https://doi.org/10.21873/anticanres.16211

Article  CAS  PubMed  Google Scholar 

Agema BC, Veerman GDM, Steendam CMJ, Lanser DAC, Preijers T, van der Leest C, Koch BCP, Dingemans AC, Mathijssen RHJ, Koolen SLW (2022) Improving the tolerability of osimertinib by identifying its toxic limit. Ther Adv Med Oncol 14:17588359221103212. https://doi.org/10.1177/17588359221103212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA (2016) Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol 77:767–776. https://doi.org/10.1007/s00280-016-2992-z

Article  CAS  PubMed  Google Scholar 

Heersche N, Veerman GDM, de With M, Bins S, Assaraf YG, Dingemans AC, van Schaik RHN, Mathijssen RHJ, Jansman FGA (2022) Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer. Drug Resist Updat 62:100832. https://doi.org/10.1016/j.drup.2022.100832

Article  CAS  PubMed  Google Scholar 

TAGRISSO® (osimertinib) tablets, for oral use Initial U.S. approval: 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf

Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, Mathijssen RHJ (2023) Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine 59:101955. https://doi.org/10.1016/j.eclinm.2023.101955

Article  PubMed  PubMed Central  Google Scholar 

Yokota H, Sato K, Sakamoto S, Okuda Y, Fukuda N, Asano M, Takeda M, Nakayama K, Miura M (2022) Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Invest New Drugs 40:1254–1262. https://doi.org/10.1007/s10637-022-01304-9

Article  CAS  PubMed  Google Scholar 

Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R (2020) Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther 215:107627. https://doi.org/10.1016/j.pharmthera.2020.107627

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD (2015) Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther 98:76–86. https://doi.org/10.1002/cpt.128

Article  CAS  PubMed  Google Scholar 

Robertson GR, Liddle C, Clarke SJ (2008) Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 83:894–897. https://doi.org/10.1038/clpt.2008.55

Article  CAS  PubMed  Google Scholar 

Sansone P, Bromberg J (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005–1014. https://doi.org/10.1200/jco.2010.31.8907

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904–910. https://doi.org/10.1016/j.ctrv.2012.04.007

Article  CAS  PubMed  Google Scholar 

Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ (2001) The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22:2243–2252. https://doi.org/10.1053/euhj.2001.2678

Article  CAS  PubMed  Google Scholar 

Koh SJ, Jang Y, Hyun YJ, Park JY, Song YD, Shin KK, Chae JS, Kim BK, Ordovas JM, Lee JH (2009) Interleukin-6 (IL-6) -572C–>G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clin Endocrinol (Oxf) 70:238–244. https://doi.org/10.1111/j.1365-2265.2008.03315.x

Article  CAS  PubMed  Google Scholar 

Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, Wang J, Li B (2018) Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget 9:12351–12364. https://doi.org/10.18632/oncotarget.24033

Article  PubMed  PubMed Central  Google Scholar 

Zhou L, Zheng Y, Tian T, Liu K, Wang M, Lin S, Deng Y, Dai C, Xu P, Hao Q, Kang H, Dai Z (2018) Associations of interleukin-6 gene polymorphisms with cancer risk: evidence based on 49,408 cancer cases and 61,790 controls. Gene 670:136–147. https://doi.org/10.1016/j.gene.2018.05.104

Article  CAS  PubMed  Google Scholar 

Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P (2007) Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res 150:101–105. https://doi.org/10.1016/j.trsl.2007.03.003

Article  CAS  PubMed  Google Scholar 

Zhu RM, Lin W, Zhang W, Ren JT, Su Y, He JR, Lin Y, Su FX, Xie XM, Tang LY, Ren ZF (2017) Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival. PLoS ONE 7:12:e0178850. https://doi.org/10.1371/journal.pone.0178850

Article  CAS  Google Scholar 

Aitken AE, Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2 C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687–1693. https://doi.org/10.1124/dmd.107.015511

Article  CAS  PubMed  Google Scholar 

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415–1422. https://doi.org/10.1124/dmd.111.038679

Article  CAS  PubMed  Google Scholar 

Mimura H, Kobayashi K, Xu L, Hashimoto M, Ejiri Y, Hosoda M, Chiba K (2015) Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4. Drug Metab Pharmacokinet 30:105–110. https://doi.org/10.1016/j.dmpk.2014.09.004

Article  CAS  PubMed  Google Scholar 

Chen Y, Ma F, Jones N, Deng R, Li C, Li CC (2024) Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based Pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 13:234–246. https://doi.org/10.1002/psp4.13073

Article  CAS